Glenza 160MG Tablet is a pharmaceutical product that contains Enzalutamide as its active ingredient, with each tablet delivering a potent dose of 160 mg. This medication is primarily indicated for the treatment of prostate cancer, particularly in patients with metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide works by inhibiting the androgen receptor signaling pathway, which is crucial for the growth and proliferation of prostate cancer cells. The formulation of Glenza is designed to provide effective management of advanced prostate cancer, helping to prolong survival and improve the quality of life for patients. As a targeted therapy, Glenza is part of a broader category of cancer treatments that focus on specific molecular targets associated with cancer progression. It is essential for patients to understand the composition and purpose of Glenza to ensure its appropriate use in their treatment regimen.